跳至主要内容
临床试验/CTRI/2017/12/010856
CTRI/2017/12/010856已完成2 期

Effect of ayurvedic drug KAL-10 on lowering hyperglycemic in subjects with diabetes: A Randomized Placebo Controlled trial.

Kerala Ayurveda Limited0 个研究点目标入组 150 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Informed consent obtained before any trial-related activities
  • Male or female patients between 18 to 70 years of age
  • Newly diagnosed with hyperglycemia
  • FBSââ?°Â¥110 mg/dL but ââ?°Â¤200 mg/dL, measured on day-1
  • PPBS >120 mg/dL and ââ?°Â¤ 200 mg/dL
  • HbA1c 6% ââ?°Â¥ & ââ?°Â¤ 10%
  • C peptide ââ?°Â¥ 1.0 ng/ml
  • Ability to comply with study requirements

排除标准

  • Females who are pregnant and/or lactating and/or sexually active but not using an acceptable method of contraception
  • History of allergy or contraindications to the ingredients present in the drug
  • History of uncontrolled or poorly controlled serum cholesterol
  • Renal impairment/insufficiency (i.e., nephritis, polycystic kidney disease, acute or chronic renal failure, end stage renal disease, >1.5 times the upper limit of normal (ULN) of serum Creatinine, etc.)
  • AST, ALT >3 times the ULN
  • Thyroid dysfunction
  • Gastrointestinal disorders (ulcerative colitis, etc.)
  • Hepatic impairment/ acute liver disease or persistent elevations in liver function tests (3 times the upper limit of normal (ULN) of LFT Uncontrolled hypertension, as defined by SBP >160 mmHg or DBP >100 mmHg while on anti-hypertensive medication

研究者

相似试验